🔗 Visit the ClinicalTrials.gov page for NCT02444793
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Combination cancer immunotherapies tailored to the tumour microenvironment. | Nat Rev Clin Oncol | 2015 | 1.54 |
| 2 | Roles of regulatory T cells in cancer immunity. | Int Immunol | 2016 | 0.95 |
| 3 | Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. | Immunotherapy | 2015 | 0.81 |
| 4 | New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. | Clin Cancer Res | 2015 | 0.78 |
| 5 | Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. | J Immunol Res | 2015 | 0.78 |
| 6 | Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. | J Immunother Cancer | 2016 | 0.75 |
| 7 | Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. | Oral Oncol | 2016 | 0.75 |